CHAPTER 9: Oligonucleotide Targeting of Long Non-coding RNAs

I. Blokhin, O. Khorkova, J. Hsiao, Claes R Wahlestedt

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In recent years, it has been shown that the central dogma of molecular biology with an underlying "one gene-one protein" concept is no longer viable. Instead, the transcriptome is dominated by non-coding RNA transcripts. Several classes of non-coding RNAs, including ribosomal RNAs, transport RNAs, microRNAs, small nuclear RNAs and a few others have been relatively well characterized. At the same time, there is one family in the non-coding transcriptome, long non-coding RNAs (lncRNAs), which, despite being the most abundant, remains structurally and functionally mysterious. Initially considered to be transcriptional noise, lncRNAs have now come under intense scrutiny, and the number of papers on lncRNAs has grown exponentially. Due to their ability to interact with virtually all classes of biomolecules, lncRNAs appear to have unique and enormous functional potential. Such a broad action of lncRNAs promises potential therapeutic implications. It is challenging to target lncRNAs by traditional medicines, such as small molecules and antibodies, but oligonucleotide-based therapies, which have been considerably improved within the last two decades, may be a perfect match. Despite translational studies of lncRNAs being in their infancy, these approaches already appear to be of therapeutic value. Here we discuss basic biology and functions of lncRNAs as well as lncRNA-dependent mechanisms of pathogenesis. We also discuss oligonucleotide-based drugs as a tool to harness those mechanisms for therapeutic purposes.

Original languageEnglish (US)
Title of host publicationTherapies for Retinal Degeneration
Subtitle of host publicationTargeting Common Processes
EditorsSudhir Agrawal, Michael J. Gait
PublisherRoyal Society of Chemistry
Pages181-205
Number of pages25
Edition68
DOIs
StatePublished - Jan 1 2019

Publication series

NameRSC Drug Discovery Series
Number68
Volume2019-January
ISSN (Print)2041-3203
ISSN (Electronic)2041-3211

Fingerprint

Long Noncoding RNA
Oligonucleotides
Untranslated RNA
Transcriptome
RNA Transport
Small Nuclear RNA
Aptitude
Ribosomal RNA
Traditional Medicine
Therapeutics
MicroRNAs
Noise
Molecular Biology
RNA

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Blokhin, I., Khorkova, O., Hsiao, J., & Wahlestedt, C. R. (2019). CHAPTER 9: Oligonucleotide Targeting of Long Non-coding RNAs. In S. Agrawal, & M. J. Gait (Eds.), Therapies for Retinal Degeneration: Targeting Common Processes (68 ed., pp. 181-205). (RSC Drug Discovery Series; Vol. 2019-January, No. 68). Royal Society of Chemistry. https://doi.org/10.1039/9781788015714-00181

CHAPTER 9 : Oligonucleotide Targeting of Long Non-coding RNAs. / Blokhin, I.; Khorkova, O.; Hsiao, J.; Wahlestedt, Claes R.

Therapies for Retinal Degeneration: Targeting Common Processes. ed. / Sudhir Agrawal; Michael J. Gait. 68. ed. Royal Society of Chemistry, 2019. p. 181-205 (RSC Drug Discovery Series; Vol. 2019-January, No. 68).

Research output: Chapter in Book/Report/Conference proceedingChapter

Blokhin, I, Khorkova, O, Hsiao, J & Wahlestedt, CR 2019, CHAPTER 9: Oligonucleotide Targeting of Long Non-coding RNAs. in S Agrawal & MJ Gait (eds), Therapies for Retinal Degeneration: Targeting Common Processes. 68 edn, RSC Drug Discovery Series, no. 68, vol. 2019-January, Royal Society of Chemistry, pp. 181-205. https://doi.org/10.1039/9781788015714-00181
Blokhin I, Khorkova O, Hsiao J, Wahlestedt CR. CHAPTER 9: Oligonucleotide Targeting of Long Non-coding RNAs. In Agrawal S, Gait MJ, editors, Therapies for Retinal Degeneration: Targeting Common Processes. 68 ed. Royal Society of Chemistry. 2019. p. 181-205. (RSC Drug Discovery Series; 68). https://doi.org/10.1039/9781788015714-00181
Blokhin, I. ; Khorkova, O. ; Hsiao, J. ; Wahlestedt, Claes R. / CHAPTER 9 : Oligonucleotide Targeting of Long Non-coding RNAs. Therapies for Retinal Degeneration: Targeting Common Processes. editor / Sudhir Agrawal ; Michael J. Gait. 68. ed. Royal Society of Chemistry, 2019. pp. 181-205 (RSC Drug Discovery Series; 68).
@inbook{67203cb49b40444d914733c136250d6a,
title = "CHAPTER 9: Oligonucleotide Targeting of Long Non-coding RNAs",
abstract = "In recent years, it has been shown that the central dogma of molecular biology with an underlying {"}one gene-one protein{"} concept is no longer viable. Instead, the transcriptome is dominated by non-coding RNA transcripts. Several classes of non-coding RNAs, including ribosomal RNAs, transport RNAs, microRNAs, small nuclear RNAs and a few others have been relatively well characterized. At the same time, there is one family in the non-coding transcriptome, long non-coding RNAs (lncRNAs), which, despite being the most abundant, remains structurally and functionally mysterious. Initially considered to be transcriptional noise, lncRNAs have now come under intense scrutiny, and the number of papers on lncRNAs has grown exponentially. Due to their ability to interact with virtually all classes of biomolecules, lncRNAs appear to have unique and enormous functional potential. Such a broad action of lncRNAs promises potential therapeutic implications. It is challenging to target lncRNAs by traditional medicines, such as small molecules and antibodies, but oligonucleotide-based therapies, which have been considerably improved within the last two decades, may be a perfect match. Despite translational studies of lncRNAs being in their infancy, these approaches already appear to be of therapeutic value. Here we discuss basic biology and functions of lncRNAs as well as lncRNA-dependent mechanisms of pathogenesis. We also discuss oligonucleotide-based drugs as a tool to harness those mechanisms for therapeutic purposes.",
author = "I. Blokhin and O. Khorkova and J. Hsiao and Wahlestedt, {Claes R}",
year = "2019",
month = "1",
day = "1",
doi = "10.1039/9781788015714-00181",
language = "English (US)",
series = "RSC Drug Discovery Series",
publisher = "Royal Society of Chemistry",
number = "68",
pages = "181--205",
editor = "Sudhir Agrawal and Gait, {Michael J.}",
booktitle = "Therapies for Retinal Degeneration",
address = "United Kingdom",
edition = "68",

}

TY - CHAP

T1 - CHAPTER 9

T2 - Oligonucleotide Targeting of Long Non-coding RNAs

AU - Blokhin, I.

AU - Khorkova, O.

AU - Hsiao, J.

AU - Wahlestedt, Claes R

PY - 2019/1/1

Y1 - 2019/1/1

N2 - In recent years, it has been shown that the central dogma of molecular biology with an underlying "one gene-one protein" concept is no longer viable. Instead, the transcriptome is dominated by non-coding RNA transcripts. Several classes of non-coding RNAs, including ribosomal RNAs, transport RNAs, microRNAs, small nuclear RNAs and a few others have been relatively well characterized. At the same time, there is one family in the non-coding transcriptome, long non-coding RNAs (lncRNAs), which, despite being the most abundant, remains structurally and functionally mysterious. Initially considered to be transcriptional noise, lncRNAs have now come under intense scrutiny, and the number of papers on lncRNAs has grown exponentially. Due to their ability to interact with virtually all classes of biomolecules, lncRNAs appear to have unique and enormous functional potential. Such a broad action of lncRNAs promises potential therapeutic implications. It is challenging to target lncRNAs by traditional medicines, such as small molecules and antibodies, but oligonucleotide-based therapies, which have been considerably improved within the last two decades, may be a perfect match. Despite translational studies of lncRNAs being in their infancy, these approaches already appear to be of therapeutic value. Here we discuss basic biology and functions of lncRNAs as well as lncRNA-dependent mechanisms of pathogenesis. We also discuss oligonucleotide-based drugs as a tool to harness those mechanisms for therapeutic purposes.

AB - In recent years, it has been shown that the central dogma of molecular biology with an underlying "one gene-one protein" concept is no longer viable. Instead, the transcriptome is dominated by non-coding RNA transcripts. Several classes of non-coding RNAs, including ribosomal RNAs, transport RNAs, microRNAs, small nuclear RNAs and a few others have been relatively well characterized. At the same time, there is one family in the non-coding transcriptome, long non-coding RNAs (lncRNAs), which, despite being the most abundant, remains structurally and functionally mysterious. Initially considered to be transcriptional noise, lncRNAs have now come under intense scrutiny, and the number of papers on lncRNAs has grown exponentially. Due to their ability to interact with virtually all classes of biomolecules, lncRNAs appear to have unique and enormous functional potential. Such a broad action of lncRNAs promises potential therapeutic implications. It is challenging to target lncRNAs by traditional medicines, such as small molecules and antibodies, but oligonucleotide-based therapies, which have been considerably improved within the last two decades, may be a perfect match. Despite translational studies of lncRNAs being in their infancy, these approaches already appear to be of therapeutic value. Here we discuss basic biology and functions of lncRNAs as well as lncRNA-dependent mechanisms of pathogenesis. We also discuss oligonucleotide-based drugs as a tool to harness those mechanisms for therapeutic purposes.

UR - http://www.scopus.com/inward/record.url?scp=85062405293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062405293&partnerID=8YFLogxK

U2 - 10.1039/9781788015714-00181

DO - 10.1039/9781788015714-00181

M3 - Chapter

AN - SCOPUS:85062405293

T3 - RSC Drug Discovery Series

SP - 181

EP - 205

BT - Therapies for Retinal Degeneration

A2 - Agrawal, Sudhir

A2 - Gait, Michael J.

PB - Royal Society of Chemistry

ER -